Want to see VVOS full AI Analyst Report?
Vivos Therapeutics (VVOS) Stock Statistics & Valuation Metrics
Total Valuation
Vivos Therapeutics has a market cap or net worth of $3.82M. The enterprise value is $19.70M.
- Market Cap
- $3.82M
- Enterprise Value
- $19.70M
Share Statistics
Vivos Therapeutics has 33,609,394 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 33,609,394
- Owned by Insiders
- 5.26%
- Owned by Institutions
- 0.10%
Financial Efficiency
Vivos Therapeutics’s return on equity (ROE) is 14.25 and return on invested capital (ROIC) is -123.14%.
- Return on Equity (ROE)
- 14.25
- Return on Assets (ROA)
- -0.84
- Return on Invested Capital (ROIC)
- -123.14%
- Return on Capital Employed (ROCE)
- -2.81
- Revenue Per Employee
- 65.09K
- Profits Per Employee
- -79.22K
- Employee Count
- 268
- Asset Turnover
- 0.69
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Vivos Therapeutics is -0.06. Vivos Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.06
- PS Ratio
- 0.08
- PB Ratio
- -0.53
- Price to FCF
- -0.09
- Price to Operating Cash Flow
- -0.12
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 17.44M and earned -21.23M in profits. Earnings per share was -2.06.
- Revenue
- 17.44M
- Gross Profit
- 10.54M
- Operating Income
- -19.89M
- Pretax Income
- -21.23M
- Net Income
- -21.23M
- EBITDA
- -19.92M
- Earnings Per Share (EPS)
- -2.06
Cash Flow
In the last 12 months, operating cash flow was -17.13M and capital expenditures -810,000, giving a free cash flow of -17.92M billion.
- Operating Cash Flow
- -17.13M
- Free Cash Flow
- -17.92M
- Free Cash Flow per Share
- -1.01
Dividends & Yields
Vivos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1133.50%
- Earnings Yield
- -1271.54%
Stock Price Statistics
- Beta
- 0.49
- 52-Week Price Change
- -95.62%
- 50-Day Moving Average
- 0.17
- 200-Day Moving Average
- 0.73
- Relative Strength Index (RSI)
- 26.75
- Average Volume (3m)
- 14.52M
Important Dates
Vivos Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Vivos Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of -906.17%
- Current Ratio
- 0.24
- Quick Ratio
- 0.24
- Debt to Market Cap
- 0.42
- Net Debt to EBITDA
- -0.58
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Vivos Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Vivos Therapeutics EV to EBITDA ratio is -0.53, with an EV/FCF ratio of -0.67.
- EV to Sales
- 0.57
- EV to EBITDA
- -0.53
- EV to Free Cash Flow
- -0.67
- EV to Operating Cash Flow
- -0.70
Balance Sheet
Vivos Therapeutics has $1.77M in cash and marketable securities with $12.14M in debt, giving a net cash position of -$10.37M billion.
- Cash & Marketable Securities
- $1.77M
- Total Debt
- $12.14M
- Net Cash
- -$10.37M
- Net Cash Per Share
- -$0.31
- Tangible Book Value Per Share
- -$0.92
Margins
Gross margin is 59.72%, with operating margin of -107.92%, and net profit margin of -122.42%.
- Gross Margin
- 59.72%
- Operating Margin
- -107.92%
- Pretax Margin
- -122.62%
- Net Profit Margin
- -122.42%
- EBITDA Margin
- -108.78%
- EBIT Margin
- -117.35%
Analyst Forecast
The average price target for Vivos Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 45.21%
- EPS Growth Forecast
- -10.29%
Scores
- Smart Score
- ―
- AI Score
- 43